Display options
Cite
Puxeddu I, Ferro F, Bartoloni E, et al. COVID-19: the new challenge for rheumatologists. One year later. Clin Exp Rheumatol. 2021;39(1):203-213
Puxeddu, I., Ferro, F., Bartoloni, E., Elefante, E., Baldini, C., Scirè, C., Talarico, R., Migliorini, P., Mosca, M., & Bombardieri, S. (2021). COVID-19: the new challenge for rheumatologists. One year later. Clinical and experimental rheumatology, 39(1), 203-213.
Puxeddu, Ilaria, et al. "COVID-19: the new challenge for rheumatologists. One year later." Clinical and experimental rheumatology vol. 39,1 (2021): 203-213.
Puxeddu I, Ferro F, Bartoloni E, Elefante E, Baldini C, Scirè C, Talarico R, Migliorini P, Mosca M, Bombardieri S. COVID-19: the new challenge for rheumatologists. One year later. Clin Exp Rheumatol. 2021 Jan-Feb;39(1):203-213. Epub 2021 Feb 05. PMID: 33555253.
Copy Download .nbib Format: NLM
Share it on

Clin Exp Rheumatol. 2021 Jan-Feb;39(1):203-213. Epub 2021 Feb 05.

COVID-19: the new challenge for rheumatologists. One year later.

Clinical and experimental rheumatology

Ilaria Puxeddu, Francesco Ferro, Elena Bartoloni, Elena Elefante, Chiara Baldini, Carlo Scirè, Rosaria Talarico, Paola Migliorini, Marta Mosca, Stefano Bombardieri

Affiliations

  1. Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. [email protected].
  2. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  3. Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
  4. Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.
  5. Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  6. University of Pisa, Italy.

PMID: 33555253

Abstract

At the beginning of COVID-19, we underlined that this pandemic was a new challenge for rheumatologists. On the one hand, it was necessary to clarify the impact of this new viral disease on the natural history of many rheumatic diseases and, on the other hand, to define the beneficial or harmful effects of the synthetic or targeted therapies used for their treatment. In addition, we have postulated that in view of the common pathogenetic mechanisms involved, the therapeutic armamentarium currently employed in the management of viral or idiopathic systemic autoimmune rheumatic diseases could be useful to control the "cytokine storm" induced by SARS-COV-2. One year later, in the present review we have analysed the progress of the knowledge on both these aspects and updated the algorithms initially proposed for a rational use of the synthetic and targeted anti-inflammatory and immunomodulatory agents in the management of COVID-19.

MeSH terms

Publication Types